



Invitrocue Appoints Assoc Prof Narayanan Gopalakrishna Iyer as Chair, Medical Advisory Board and Announces Changes to Executive Team

October 19, 2018 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, today announced the appointment of Assoc Prof Narayanan Gopalakrishna Iyer as Chair, Medical Advisory Board (MAB) and the termination of Dr Ramanuj DasGupta as Chief Scientific Officer (Non-Executive) of the company effective 30 November 2018.

Invitrocue's Medical Advisory Board consists of highly experienced and internationally respected oncology experts from Asia, Australia and Europe. The advisors provide guidance to the management team on the development of Onco-PDO and the strategic expansion of the personalised tumour test business unit. The appointment of Assoc Prof Iyer as Chair of the MAB demonstrates Invitrocue's commitment to build expertise within the company as it evolves from a research-stage organisation to one with a highly-strategic commercial focus built on a foundation of rigorous clinical research.

Assoc Prof Iyer has been a member of the Medical Advisory Board since 2017 and will assume the role of Chair with immediate effect. He currently leads the Cancer Therapeutics Research Laboratory at the National Cancer Centre of Singapore (NCCS) and is a Head and Neck surgeon at NCCS and Singapore General Hospital. He is also a Head and Senior Consultant at SingHealth Duke-NUS' Head and Neck Centre and previously completed surgical fellowships in Australia and the US.

As a clinician scientist, Assoc Prof Iyer is also actively involved in research and leads a number of research programs that aim to determine prognostic factors in oral cancers, identifying the cause of head and neck cancers in young people and development of novel therapeutic strategies in treating these cancers. His research on the use of biomarkers to facilitate personalized patient-selection strategies has been published in prestigious journals including *Nature Medicine*.

Commenting on the appointment, Dr. Steven Fang, Executive Director, Invitrocue, said:

"We are delighted that Assoc Prof Iyer has accepted the role of Chair of our Medical Advisory Board. His appointment comes at an important time for Invitrocue as our team focuses on translating our strong scientific evidence to drive the successful commercialisation of Onco-PDO. Assoc Prof Iyer has already shared valuable insights with us since joining the Medical Advisory Board and we look forward to the contributions of the Medical Advisory Board in shaping our clinical and commercial strategies to realise the broad potential of Onco-PDO under his leadership."

-ENDS-

For more information contact:

Martin D. Bach, VP Operations
T: +65 6460 0497
martind.bach@invitrocue.com

Invitrocue Limited | ACN 009 366 009
Level 2, 350 Kent Street, Sydney, NSW, 2000, Australia





About Invitrocue

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue's Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com

